Business
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer
Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the appointment of Marc Grasso, M.D., as its Chief Financial Officer (CFO), effective today. Dr. Grasso brings more than 25 years of public company, capital markets, and investment banking management experience to the role. He succeeds Ryan Jones, MBA, who will move to a strategic advisor role to ensure a seamless tra
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"Dr. Marc Grasso brings more than 25 years of public company, capital markets and investment banking expertise to the role","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"EMERYVILLE, Calif., June 30, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the appointment of Marc Grasso, M.D., as its Chief Financial Officer (CFO), effective today. Dr. Grasso brings more than 25 years of public company, capital markets, and investment banking management experience to the role. He succeeds Ryan Jones, MBA, who will move to a strategic advisor role to ensure a seamless transition.","length":564,"tagName":"p"},{"type":"image","alt":"Kyverna Therapeutics","displaySize":"","headline":null,"caption":"Kyverna Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":109,"url":"https://media.zenfs.com/en/prnewswire.com/0c757be00f29b02dae6940cfed1a6c3b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tzF6X1AYaE26Z1Rx9CtRbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0c757be00f29b02dae6940cfed1a6c3b","width":400,"height":109}},"href":"https://mma.prnewswire.com/media/2721393/Kyverna_Primary_Full_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are excited to welcome Marc, an accomplished life-sciences leader with a proven track record working in capital markets and driving financial discipline and operational execution in maturing public companies," said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. "As we continue to accelerate our clinical development and commercialization efforts, Marc's leadership will be instrumental in supporting our next phase of growth and advancing our mission to bring the transformative potential of CAR T-cell therapy to patients with autoimmune diseases. On behalf of the Kyverna leadership team, I'd also like to thank Ryan, one of Kyverna's first employees, for the significant contributions he has made throughout his tenure with the Company." ","length":801,"tagName":"p"},{"type":"text","content":"Most recently, Dr. Grasso served as CFO of Alector, Inc., a clinical-sta...